Skip to main content

Peizer Terren S's Form 4 filing

Biovie Inc.BIVI · filed Aug 26, 2022

Accession no.
0001520138-22-000381
Filed
Aug 26, 2022, 5:10 PM ET
Trade date
Jul 3, 2018-Jun 10, 2021
Filing delay
1,515 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 9 non-derivative transactions and 10 derivative transactions. It was filed 1515 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Peizer Terren SCIK 0000904534Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 13, 2018Common StockCConversionAcquired+1,600,000–F1–1,600,000Indirect
Jan 2, 2019Common StockAGrant or awardAcquired+1,600$0.00$01,601,600Direct
Jun 24, 2019Common StockAGrant or awardAcquired+1,526,334$45.00+$68,685,0303,127,934Indirect
Sep 24, 2019Common StockAGrant or awardAcquired+1,125,000–F6–4,252,934Indirect
Jan 2, 2020Common StockAGrant or awardAcquired+4,422–F7–4,257,356Indirect
Jan 2, 2020Common StockAGrant or awardAcquired+1,600$0.00$04,258,956Direct
Sep 22, 2020Common StockAGrant or awardAcquired+5,359,832–F8–9,618,788Indirect
Sep 22, 2020Common StockMOption exerciseAcquired+1,549,750$0.0001+$154.9811,168,538Indirect
Jun 10, 2021Common StockAGrant or awardAcquired+8,361,308–F9–19,529,846Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 3, 2018Common StockPPurchaseAcquired+1,600,000–F10–1,600,000Indirect
Jul 3, 2018Common StockPPurchaseAcquired+1,713,331–F10–1,713,331Indirect
Aug 3, 2018Common StockCConversionDisposed−1,600,000–F10–0Indirect
Jun 24, 2019Common StockDReturned to the companyDisposed−1,713,331–F5–0Indirect
Sep 24, 201910% Convertible Debenture due 2020AGrant or awardAcquired––F6––Indirect
Sep 24, 2019Common StockAGrant or awardAcquired+1,250,000–F6–1,250,000Indirect
Jul 13, 2020Common StockAGrant or awardAcquired+299,750–F6–299,750Indirect
Sep 22, 202010% Convertible Debenture due 2020DReturned to the companyDisposed–$0.00–0Indirect
Sep 22, 2020Common StockMOption exerciseDisposed−1,250,000–F8–0Indirect
Sep 22, 2020Common StockMOption exerciseDisposed−299,750–F8–0Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

See Exhibit 99.1

Referenced by the price of 1 transaction in Table I.

F5

Pursuant to a letter agreement with the Issuer dated June 24, 2019, Acuitas agreed to modify its existing rights under the 2018 SPA and agreed to immediately exchange the 2018 Warrants such that it effectively exercised its warrant in full pursuant to a cashless exercise thereof at an assumed then-current market price of $45 per share (adjusted to reflect the Reverse Stock Split) and, as a result, received an aggregate of 95% of the shares covered thereby.

Referenced by the price of 1 transaction in Table II.

F6

See Exhibit 99.1

Referenced by the price of 1 transaction in Table I and 3 transactions in Table II.

F7

The Issuer paid $13,487 of accrued interest on the Debenture through the issuance of 4,422 shares of the Issuer's common stock to Acuitas.

Referenced by the price of 1 transaction in Table I.

F8

See Exhibit 99.1

Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.

F9

The Issuer issued these shares to NeurMedix, Inc. ("NeurMedix") in partial consideration for the acquisition of certain assets from NeurMedix and the assumption of certain liabilities of NeurMedix pursuant to the Asset Purchase Agreement, dated April 27, 2021, by and among the Issuer, NeurMedix, Inc. and Acuitas. In connection with the closing, NeurMedix assigned the rights to receive such shares to Acuitas.

Referenced by the price of 1 transaction in Table I.

F10

See Exhibit 99.1

Referenced by the price of 3 transactions in Table II.

Remarks

Exhibit 99.1 - Explanation of Responses

Read the full filing on SEC EDGAR (opens in a new tab)